Core Viewpoint - Meibang Co., Ltd. experienced abnormal stock price fluctuations, with a cumulative increase of over 20% in closing prices over two consecutive trading days [1] Summary by Relevant Sections Stock Performance - Meibang Co., Ltd. stock closed with a price increase deviation of over 20% on July 17 and July 18, indicating abnormal trading activity [1] Shareholder Actions - The company disclosed a share reduction plan on June 4, 2025, where Meiping Consulting intends to reduce holdings by no more than 1.2488 million shares, and Hao Xinxin plans to reduce by no more than 1.0674 million shares [1] - During the period of abnormal stock fluctuations, Meiping Consulting and Hao Xinxin executed share reductions through block trading on July 17 and July 18, consistent with the previously announced reduction plan, confirming no violations occurred [1]

2连板美邦股份（605033）公告，公司股票于2025年7月17日、7月18日连续2个交易日收盘价格涨幅偏离 值累计超过20%，属于股票交易异常波动情形。2025年6月4日，公司披露了股东减持股份计划公告，美 平咨询拟减持不超过124.88万股，郝新新拟减持不超过106.74万股。异常波动期间，美平咨询、郝新新 存在通过大宗交易减持公司股票的情形，与此前披露的减持计划一致，不存在违规减持情形。 ...

Group 1: Stock Performance - Zhejiang Zhenyuan and Asia-Pacific Pharmaceutical both achieved a 2-day limit-up with increases of 10.01% and 9.98% respectively, driven by innovation in pharmaceuticals [2] - Chengdu XianDao saw a first board listing with a significant rise of 20.02%, attributed to innovative drug developments [2] - TaiJing Technology and YanHua Intelligent both recorded first board listings with increases of 9.97% and 9.94%, linked to Huawei's influence in robotics [5] Group 2: AI and Robotics - Nvidia's CEO suggested that Huawei's AI chips could potentially replace Nvidia's offerings, indicating a competitive shift in the AI chip market [4] - The domestic robotics industry is gaining traction with significant orders being awarded, highlighting its importance in national competition [7] Group 3: Market Trends - The light communication sector is expected to see sustained growth due to high demand in both domestic and international markets, with performance likely to continue improving [13] - The low-altitude economy is gaining attention, with a notable $1 billion procurement agreement signed for eVTOL aircraft, indicating growth potential in this sector [17] Group 4: Consumer and Retail - The Chinese government is implementing measures to boost consumer spending, which is expected to positively impact the retail sector [21] - Companies like Guoguang Chain and Hanshang Group have seen first board listings with increases of 9.98% and 9.97%, reflecting the positive sentiment in the retail market [23] Group 5: Solar and Food & Beverage - The price of polysilicon has increased by 12.4% week-on-week, indicating a rising trend in the solar industry [24] - The food and beverage sector is also benefiting from government initiatives aimed at enhancing consumer demand, with companies like Huangshi Group seeing a 10.10% increase [26]

Core Viewpoint - The announcement details the share reduction plans of Meiping Consulting and Meifu Consulting, which are significant shareholders of Meibang Co., indicating a potential shift in ownership dynamics and market sentiment towards the company [1][2][3] Summary by Sections Share Reduction Plans - Meiping Consulting plans to reduce its holdings by up to 1,248,821 shares, representing 0.92% of the total share capital, with a breakdown of 416,274 shares through centralized bidding and 832,547 shares through block trading [1] - Meifu Consulting intends to reduce its holdings by up to 1,739,811 shares, representing 1.29% of the total share capital, with 579,937 shares through centralized bidding and 1,159,874 shares through block trading [1] Recent Transactions - On July 7, 2025, Meiping Consulting reduced its holdings by 291,300 shares (0.22% of total share capital) at a price range of 19.2125 to 19.6500 CNY per share, totaling 5,673,068.00 CNY [2] - Meifu Consulting reduced its holdings by 405,900 shares (0.30% of total share capital) at a price range of 19.2300 to 19.6500 CNY per share, totaling 7,904,657.00 CNY [2] Ownership Changes - The combined shareholding of Meiping Consulting and Meifu Consulting decreased from 69.09% to 68.57% following the recent reductions [2] - After the reductions, Meiping Consulting holds 3,218,700 shares (2.38% of total share capital) and Meifu Consulting holds 4,484,100 shares (3.32% of total share capital) [3] - The share reductions are characterized as normal actions by the shareholders and are not expected to significantly impact the company's governance structure or ongoing operations [3]

Core Viewpoint - The announcement details the progress of share reduction by major shareholders of Shaanxi Meibang Pharmaceutical Group Co., Ltd., indicating a decrease in their holdings and the implications of this reduction on the company's equity structure [1][2]. Shareholder Holding Situation - Meiping Consulting holds 3,510,000 shares, accounting for 2.60% of the total share capital, while Meifu Consulting holds 4,890,000 shares, representing 3.62% of the total share capital. Both holdings originated from shares acquired before the company's initial public offering (IPO) [1][2]. Reduction Plan Progress - Meiping Consulting plans to reduce its holdings by up to 1,248,821 shares (0.92% of total share capital), with a breakdown of 416,274 shares through centralized bidding and 832,547 shares via block trading. Meifu Consulting intends to reduce its holdings by up to 1,739,811 shares (1.29%), with 579,937 shares through centralized bidding and 1,159,874 shares via block trading [1][2]. - As of the announcement date, Meiping Consulting has reduced its holdings by 291,300 shares (0.22%), decreasing its ownership from 2.60% to 2.38%. Meifu Consulting has reduced its holdings by 405,900 shares (0.30%), lowering its ownership from 3.62% to 3.32%. The combined ownership of Meiping Consulting, Meifu Consulting, and their concerted parties has decreased from 69.09% to 68.57% [1][3]. Compliance with Regulations - The reduction in shareholding has triggered a change in equity structure that meets the regulatory requirements outlined in the "Management Measures for the Acquisition of Listed Companies" [1][3].

陕西美邦药业集团股份有限公司 股东减持股份进展暨权益变动触及 1%的 提示性公告 证券代码：605033 证券简称：美邦股份 公告编号：2025-035 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，连云港美平企业管理咨询合伙企业（有限合伙）（以 下简称"美平咨询"）持有陕西美邦药业集团股份有限公司（以下简称"公司"、 "美邦股份"）股份 3,510,000 股，占公司总股本的 2.60%；连云港美富企业管 理咨询合伙企业(有限合伙)（以下简称"美富咨询"）持有公司股份 4,890,000 股，占公司总股本的 3.62%，前述股份全部来源于公司首次公开发行前已持有的 股份。 减持计划的进展情况 2025 年 6 月 4 日，公司披露了《陕西美邦药业集团股份有限公司股东减持 股份计划公告》（公告编号：2025-032），美平咨询拟通过集中竞价交易或大宗交 易方式合计减持不超过 1,248,821 股，即不超过公司总股本的 0.92%。其中以集 中竞价方式减持公司 ...

Summary of Key Points Core Viewpoint - The company, Shaanxi Meibang Pharmaceutical Group Co., Ltd., has provided a guarantee of RMB 67 million for its wholly-owned subsidiary, Shaanxi Nozheng Biotechnology Co., Ltd., to support a bank loan for the construction of a pesticide production line [1][2]. Group 1: Guarantee Details - The guarantee amount provided by the company is RMB 67 million, which is the total actual guarantee balance as of the announcement date [1]. - The loan is secured through a contract with Agricultural Bank of China for a term of 7 years, aimed at funding the first phase of a project to produce 20,000 tons of pesticide raw materials and intermediates [1][2]. - There are no counter-guarantees associated with this guarantee, and there are no overdue guarantees reported [1]. Group 2: Internal Decision-Making Process - The company held meetings on April 24, 2025, to approve the guarantee for its subsidiaries, allowing a total guarantee limit of up to RMB 700 million for the year 2025 [2]. - Prior to this guarantee, the company had no outstanding guarantees for Nozheng Biotechnology, with a remaining guarantee capacity of RMB 250 million [2]. Group 3: Subsidiary Information - Shaanxi Nozheng Biotechnology Co., Ltd. was established on March 26, 2007, with a registered capital of RMB 100 million, and operates in the pesticide and chemical intermediate sectors [3][4]. - The company has a good credit status with no significant issues affecting its debt repayment ability [4]. Group 4: Necessity and Reasonableness of the Guarantee - The guarantee is deemed necessary for supporting the subsidiary's bank loan application, allowing the company to effectively control operational risks and maintain oversight of its credit status [4]. Group 5: Board Opinions - The board of directors supports the provision of guarantees to subsidiaries to enhance operational efficiency and align with the interests of the company and its shareholders [4]. Group 6: Overall Guarantee Status - As of the announcement date, the total guarantees provided by the company to its subsidiaries amount to RMB 700 million, representing 62.24% of the company's audited net assets for 2024 [4].

证券代码：605033 证券简称：美邦股份 公告编号：2025-034 陕西美邦药业集团股份有限公司 关于为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司已于 2025 年 4 月 24 日分别召开了第三届董事会第六次会议、第三届监 事会第五次会议，并于 2025 年 5 月 16 日召开 2024 年年度股东会审议通过了《关 于公司 2025 年度为子公司提供担保预计的议案》，同意公司 2025 年度为子公司 拟提供合计不超过 70,000.00 万元的担保额度，用于满足公司及合并报表范围内 全资子公司的日常生产经营及业务发展需要。具体情况详见公司于 2025 年 4 月 26 日、2025 年 5 月 17 日披露的《陕西美邦药业集团股份有限公司关于公司 2025 年度为子公司提供担保预计的公告》（公告编号：2025-017）、《陕西美邦药业 集团股份有限公司 2024 年年度股东会决议公告》（公告编号：2025-028）。 重要内容提示: 被担保人名称：陕西诺正生物科技有限公司（以下简称" ...

一、 前次使用闲置募集资金进行现金管理到期赎回情况 单位：万元 | 受托方 | 产品 | 产品 | 金额 | 实际 收益 | 起息日 | 到期日 | 赎回 | 实际 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 类型 | 名称 | | 率 | | | 金额 | 收益 | | | | 同盈象固收 | | | | | | | | 中信银 | 银行理 | 稳健七天持 | 1,500 | 1.71% | 2025-1-3 | 2025-6-13 | 1,500 | 11.25 | | 行 | 财产品 | 有期 1 号理财 | | | | | | | | | | 产品 | | | | | | | 陕西美邦药业集团股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回 并继续进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 履行的审议程序：陕西美邦药业集团股份有限公司（以下简称"公司"） 已于 2025 年 4 ...

Core Viewpoint - The company, Shaanxi Meibang Pharmaceutical Group Co., Ltd., has announced the use of temporarily idle raised funds for cash management, specifically through a financial product with a total investment of 15 million yuan [1][4]. Group 1: Financial Management - The entrusted financial management is conducted by CITIC Bank, with a total amount of 15 million yuan allocated to the "Anying Xiang Fixed Income Stable Profit One Month Holding Period 32 C" product [1][7]. - The company aims to enhance the efficiency of fund utilization while ensuring that the investment projects funded by the raised capital are not affected [4][11]. - The maximum amount approved for cash management is 20 million yuan from idle raised funds and 60 million yuan from idle self-owned funds, with the ability to roll over the amount within the validity period of the resolution [1][8]. Group 2: Previous Financial Management - The previous financial management involved the redemption of funds from a product named "Tongying Xiang Fixed Income Stable Seven-Day Holding Product 1," with actual returns aligning with expectations [2][3]. - The company has utilized a total of 9 million yuan in financial products over the last twelve months, with a maximum single-day investment of 3 million yuan, representing 2.67% of the net assets for the past year [13]. Group 3: Investment Product Details - The current financial product has a duration of 30 days, with an expected annualized return rate of 3.86% [7]. - The company ensures that the investment products are of high safety and liquidity, complying with the requirements for cash management without altering the intended use of raised funds [6][11]. Group 4: Approval Process - The decision to use idle funds for cash management was approved during the third board meeting and the fifth supervisory board meeting held on April 24, 2025, and subsequently ratified at the annual shareholders' meeting on May 16, 2025 [1][8]. - The supervisory board and the sponsor institution have both expressed agreement with the company's cash management strategy, confirming compliance with relevant regulations [11].